
CLAIMS

1. A compound comprising formula II:




II


wherein,


R^1 denotes COOH, COOA, COA, cyano, or if n of $(R_4)_n$ is 4, R^1 also denotes $CON(R^3)_2$ or CONHA;

R^2 denotes H, Hal, A or O-A;

R^a is selected from the group consisting of







X^1, X^2 denote each independently of one another NR^c or NR^d; provided that one of X^1 and X^2 is NR^c;

R^b and R^c together represent a chemical bond;

R^d denotes H or A;

with a proviso that when R^a is , R^1 is –COOH, and n is 0, then R_2 is not Hydrogen;

Hal denotes F, Cl, Br or I;

A is a branched or linear alkyl having 1 to 12 C-atoms, wherein one or more, preferably 1 to 7 H-atoms may be replaced by $OR^3$and wherein one or more, preferably 1 to 7 non-adjacent CH_2-groups may be replaced by O, or S and/or by -CH=CH- or -C≡C- groups, or denotes cycloalkyl having 3-7 ring C atoms;

R^3 is H or alkyl;









R^4 is halo or alkoxy;









R^5 at each occurrence is independently selected from Hal, hydroxy, alkoxy, carboxy, perfluoro-alkyl, perfluoro-alkyloxy, cyano, nitro, amino, amido, or alkyl;









n denotes 0, 1, 2, 3 or 4;

















and pharmaceutically acceptable solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

















2. The compound of claim 1, selected from the group consisting of:

















	I2
	I3
	I4
	I5
	I6
	I10
	I11
	I12
	I13
	I14
	I15
	I16
	I17
	I18
	I20
	I21

















	122
	123
	124
	125
	126
	127
	128
	129

















	130
	131
	132
	133
	134
	135
	138
	141

















	144
	145
	146
	147
	148
	152
	154
	155
	156
	157
	158
	159
	160
	162
	165
	166

















	167
	168
	170
	171
	172
	173
	174
	176
	177
	178
	182
	183
	185
	186
	187
	188









	I89
	I90
	I91
	I93
	I94
	I95
	I96
	I97
	I98
	I99
	I100
	I101
	I102
	I104
	I105
	I106

	I107
	I109
	I110
	I112
	I113
	I114
	I115
	I116
	I117
	I118
	I119
	I120
	I121
	I123
	I124
	I125

	I126
	I127
	I128
	I129
	I130
	I131
	I132
	I133
	I134
	I136
	I137
	I139
	I140
	I141
	I143
	I144

	I145
	I146
	I147
	I148
	I149
	I150
	I151
	I152
	I153
	I154
	I155
	I156
	I157
	I158
	I160
	I161

	I162
	I163
	I164
	I167
	I168
	I169
	I170
	I171
	I172
	I173
	I175
	I176
	I177
	I178
	I179
	I182


	I183		I188
	I184		I189
	I185		I190
	I186		I192

and pharmaceutically acceptable solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios.

3. A pharmaceutical composition comprising at least one compound according to claim 1 and/or pharmaceutically usable tautomers, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and optionally excipients and/or adjuvants.

4. A pharmaceutical composition comprising at least one compound according to claim 1 and/or pharmaceutically usable tautomers, salts, solvates and stereoisomers thereof, including mixtures thereof in all ratios, and at least one further active ingredient.

5. Use of compounds of formula II



II

wherein, R^1, R^2, X^1, X^2, R^4, R^a, R^b and n are as defined in claim 1;

and pharmaceutically acceptable solvates, tautomers, salts and stereoisomers thereof, including mixtures thereof in all ratios as a medicament.

6. Use of compounds according to claim 1, and pharmaceutically usable salts, tautomers, solvates and stereoisomers thereof, including mixtures thereof in all ratios, in the preparation of a medicament for the treatment and/or prophylaxis of a dihydroorotate dehydrogenase associated disorder.

7. The use according to claim 6, wherein the dihydroorotate dehydrogenase associated disorder is an autoimmune disorder or condition associated with an overactive immune response.


8. Use of compounds according to claim 1, and pharmaceutically usable salts, tautomers, solvates and stereoisomers thereof, including mixtures thereof in all ratios, in the preparation of a medicament for the treatment and/or prophylaxis of an immunoregulatory abnormality.

9. The use according to claim 8, wherein the immunoregulatory abnormality is multiple sclerosis or rheumatoid arthritis.

10. Use of the compounds according to claim 1 in the preparation of a medicament for the treatment and prophylaxis of cancer diseases, inflammatory bowel disease or rheumatoid arthritis.

11. A process for the preparation of compounds of Formula (II) wherein X^1 and X^2 are NR^c or NR^d and wherein R^b and R^c together represent a chemical bond, characterized in that :


Compound (A)



(A)

wherein R^1, R^2 are as defined in claim 1,

is reacted with compound (B)



(B)

wherein R_4, n and R^a are as defined in claim 1.